Trials / Completed
CompletedNCT00790816
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 500 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lapatinib in combination with an anti-cancer agent | Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI |
| DRUG | Lapatinib | Lapatinib monotherapy |
| DRUG | Lapatinib in combination with an anti-cancer agent as specified by parent protocol | Lapatinib in combination with an anti-cancer agent as specified by parent protocol |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2016-08-19
- Completion
- 2016-08-19
- First posted
- 2008-11-14
- Last updated
- 2018-02-28
Locations
23 sites across 5 countries: United States, Canada, Netherlands, South Korea, Spain
Source: ClinicalTrials.gov record NCT00790816. Inclusion in this directory is not an endorsement.